Longitudinal changes in task-evoked brain responses in parkinson's disease patients with and without mild cognitive impairment

Frontiers in Neuroscience

Volumn , Issue 8 JUN, 2014, Pages

  Ekman, Urban ^a,b   Eriksson, Johan ^a,b   Forsgren, Lars ^a   Domellöf, Magdalena ^a   Elgh, Eva ^a   Lundquist, Anders ^a,b   Nyberg, Lars ^a,b  

^a UMEÅ UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; ATTENTION; BOLD SIGNAL; BRAIN FUNCTION; CAUDATE NUCLEUS; CLINICAL ARTICLE; COHORT ANALYSIS; DEPTH PERCEPTION; ELECTROENCEPHALOGRAM; EPISODIC MEMORY; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUSIFORM GYRUS; HUMAN; IDIOPATHIC DISEASE; LANGUAGE; LONGITUDINAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PARKINSON DISEASE; PARKINSONISM; PREFRONTAL CORTEX; TASK PERFORMANCE; WORKING MEMORY; CONTROLLED STUDY; EVOKED BRAIN STEM RESPONSE;

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

EID: 84904874228     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2014.00207     Document Type: Article

References (56)

1. Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson's disease: A multicenter pooled analysis. Neurology 2010; 75: 1062-1069.
2. Abdulkadir A, Mortamet B, Vemuri P, Clifford RJ, Krueger G, Klöppel S. Effects of hardware heterogeneity on the performance of SVM Alzheimer's disease classifier. NeuroImage 2011; 58: 785-792.
3. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Archives of Neurology 2003; 60: 1745-1748.
4. Broeders M, de Bie RMA, Belseboer DC, Speelman JD, Muslimovic D, Schmand B. Evolution of mild cognitive impairment in Parkinson's disease. Neurology 2013; 81: 346-352.
5. Burgess GC, Gray JR, Conway ARA, Braver TS. Neural mechanisms of interference control underlie the relationship between fluid intelligence and working memory span. Journal of Experimental Psychology 2011; 140: 674-692.
6. Chang C, Crottaz-Herbette S, Menon V. Temporal dynamics of basal ganglia response and connectivity during verbal working memory. NeuroImage 2007; 34: 1253-1269.
7. Cools R. Dopaminergic modulation of cognitive function - implications for L-DOPA treatment in Parkinson's disease. Neuroscience & Biobehavioral Reviews 2006; 30: 1-23.
8. Cools R, Gibbs SE, Miyakawa A, Jagust W, D'esposito M. Working memory capacity predicts dopamine synthesis capacity in the human striatum. Journal of Neuroscience 2008; 28: 1208-1212.
9. Cuortney SM, Ungerleider LG, Keil K, Haxby JV. Transient and sustained activity in a distributed neural system for human working memory. Nature 1997; 386: 608-611.
10. D'Esposito M. From cognitive to neural models of working memory. Philosophical Transactions of The Royal Society 2007; 362: 761-772.
11. Duncan J, Owen AM. Common regions of the human frontal lobe recruited by diverse cognitive demands. Trends in Neurosciences 2000; 23: 475-483.
12. Ekman U, Eriksson J, Forsgren L, Jakobson S, Riklund K, Nyberg L. Functional brain activity and presynaptic dopamine uptake in patients with Parkinson's disease and mild cognitive impairment: a cross-sectional study. The Lancet Neurology 2012; 11: 679-687.
13. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Movement Disorders 2007; 22: 1689-1707.
14. Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Human Brain Mapping 1995; 2: 189-210.
15. Friston KJ, Buechel C, Fink GR, Morris J, Rolls E, Dolan RJ. Psychophysiological and modulatory interactions in neuroimaging. NeuroImage 1997; 6: 218-229.
16. Gazzaley A, Rissman J, D'Esposito M. Functional connectivity during working memory maintenance. Cognitive, Affective & Behavioral Neuroscience 2004; 4: 580-599.
17. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 1988; 51: 745-752.
18. Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson's disease: Functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 65: 1716-1722.
19. Huang C, Tang C, Feigin A, et al. Changes in network activity with the progression of Parkinson's disease. Brain 2007; 130: 1834-1846.
20. Ito K, Nagano-Saito A, Kato T, Arahata Y, Nakamura A, Kawasumi Y. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. Brain 2002; 125: 1358-1365.
21. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: Progression to dementia. Movement Disorders 2006; 21: 1343-49.
22. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. The Lancet Neurology 2010; 9: 1200-1213.
23. Lewis SJG, Dove A, Robbins TW, Barker RA, Owen AM. Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. The Journal of Neuroscience 2003; 23: 6351-6356.
24. Lewis SJG, Shine JM, Duffy S, Halliday G, Naismith SL. Anterior cingulate integrity: Executive and neuropsychiatric features in Parkinson's disease. Movement Disorders 2012; 27: 1262-1267.
25. Litvan I, Goldman JG, Tröster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Movement Disorders 2012; 27: 349-356.
26. Lyoo CH, Jeong Y, Ryu YH, Rinne JO, Lee MS. Cerebral glucose metabolism of Parkinson's disease patients with mild cognitive impairment. European Neurology 2010; 64: 65-73.
27. Marchewka A, Kherif F, Krueger G, et al. Influence of magnetic field strength and image registration strategy on voxel-based morphometry in a study of Alzheimer's disease. Human Brain Mapping 2014; 35: 1865-1874.
28. Marklund P, Larsson A, Elgh E, et al. Temporal dynamics of basal ganglia under-recruitment in Parkinson's disease: transient caudate abnormalities during updating of working memory. Brain 2009; 132: 336-346.
29. Marsh L, Biglan K, Gerstenhaber M, Williams JR. Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Movement Disorders 2009; 24: 277-282.
30. Mattay VS, Tessitore A, Callicott JH. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Annals of Neurology 2002; 51: 156-164.
31. Monchi O, Petrides M, Mejia-Constain B, Strafella AP. Cortical activity in Parkinson's disease during executive processing depends on striatal involvement. Brain 2007; 130: 233-244.
32. Monchi O, Stoessl AJ. Imaging neural correlates of mild cognitive impairment in Parkinson's disease. The Lancet Neurology 2012; 11: 653-655.
33. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979; 134: 382-389.
34. Nagano-Saito A, Washimi Y, Arahata Y, et al. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 2005; 64: 224-229.
35. Nagano-Saito A, Habak C, Mejía-Constaín B, et al. Effect of mild cognitive impairment on the patterns of neural activity in early Parkinson's disease. Neurobiology of Aging 2014; 35: 223-231.
36. Nyberg L, Larsson A, Eriksson J, Birgander R, Sundström T, Riklund K. Comparing 1.5T and 3T bold fMRI imaging of finger tapping with familiar and novel sequences. In: Schaller B. Neuroscience imaging research trends, New York, NY: Nova Science Publishers. 2007; 161-172.
37. Nyberg L, Salami A, Andersson M, et al. Longitudinal evidence for diminished frontal cortex function in aging. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 22682-22686.
38. Owen AM. Cognitive dysfunction in Parkinson's disease: The role of frontostriatal circuitry. The Neuroscientist 2004; 10: 525-537.
39. Pagonabarraga J, Corcuera-Solano I, Vives-Gilabert Y, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B. Pattern of regional cortical thinning associated with cognitive deterioration in Parkinson's disease. PLOS One 2013; 8: e54980.
40. Pedersen K F, Larsen J P, Tysnes O-B, Alves G. Prognosis of mild cognitive impairment in early Parkinson's disease: The Norwegian Park West Study. JAMA Neurology 2013; 70: 580-586.
41. Polito C, Berti V, Ramat S, et al. Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson's disease. Neurobiology of Aging 2012; 33: 206.e29-206.e39.
42. Ramírez-Ruiz B, Martí MJ, Tolosa E, et al. Longitudinal evaluation of cerebral morphologicalchanges in Parkinson's disease with and without dementia. Journal of Neurology 2005; 252: 1345-1352.
43. Bateman RJ, Xiong C, Benzinger TLS et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. New England Journal of Medicine 2012; 369: 795-804.
44. Raz N. Regional brain changes in aging healthy adults: General trends, individual differences and modifiers. Cerebral Cortex 2005; 15: 1676-1689.
45. Richard E, Brayne C. Mild cognitive impairment - not always what it seems. Nature Reviews Neurology 2014; 10: 130-131.
46. Rinne JO, Portin R, Ruottinen H, et al. Cognitive impairment and the brain dopaminergic system in Parkinson's disease. Archives of Neurology 2000; 57: 470-475.
47. Rottschy C, Langner R, Dogan I, et al. Modelling neural correlates of working memory: a coordinate-based meta-analysis. NeuroImage 2012; 60: 830-846.
48. Sawamoto N, Piccini P, Hotton G, Pavese N, Thielemans K, Brooks DJ. Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain 2008; 131: 1294-1302.
49. Stonnington CM, Tan G, Klöppel S, et al. Interpreting scan data acquired from multiple scanners: A study with Alzheimer's disease. NeuroImage 2008; 39: 1180-1185.
50. Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. The Lancet Neurology 2012; 11: 697-707.
51. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Movement Disorders 2010; 25: 2649-2653.
52. Vazey EM, Aston-Jones G. The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease. Frontiers in Behavioral Neuroscience 2012; 6: article 48.
53. Wager TD, Smith EE. Neuroimaging studies of working memory: A meta-analysis. Cognitive, Affective & Behavioural Neuroscience 2003; 3: 255-274.
54. Weintraub D, Dietz N, Duda JE, et al. Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. Brain 2012; 135: 170-180.
55. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007; 130: 1787-1798.
56. Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. Journal of Neurology, Neurosurgery & Psychiatry 2013; 84: 1258-1264.